Cargando…
A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma
BACKGROUND: There is no standard first-line chemotherapy for recurrent/metastatic (RM) or unresectable locally advanced (LA) salivary gland carcinoma (SGC). PATIENTS AND METHODS: We conducted a single institution, open-label, single arm, phase II trial of combined androgen blockade (CAB) for androge...
Autores principales: | Fushimi, C, Tada, Y, Takahashi, H, Nagao, T, Ojiri, H, Masubuchi, T, Matsuki, T, Miura, K, Kawakita, D, Hirai, H, Hoshino, E, Kamata, S, Saotome, T |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5913639/ https://www.ncbi.nlm.nih.gov/pubmed/29211833 http://dx.doi.org/10.1093/annonc/mdx771 |
Ejemplares similares
-
Predictive and Prognostic Biomarker Identification in a Large Cohort of Androgen Receptor-Positive Salivary Duct Carcinoma Patients Scheduled for Combined Androgen Blockade
por: Lassche, Gerben, et al.
Publicado: (2021) -
Multicentre, retrospective study of the efficacy and safety of nivolumab for recurrent and metastatic salivary gland carcinoma
por: Niwa, Kazutomo, et al.
Publicado: (2020) -
Survival benefit of HER2-targeted or androgen deprivation therapy in
salivary duct carcinoma
por: Kawakita, Daisuke, et al.
Publicado: (2022) -
Androgen Receptor Signaling in Salivary Gland Cancer
por: Dalin, Martin G., et al.
Publicado: (2017) -
The Role of the EZH2 and H3K27me3 Expression as a Predictor of Clinical Outcomes in Salivary Duct Carcinoma Patients: A Large-Series Study With Emphasis on the Relevance to the Combined Androgen Blockade and HER2-Targeted Therapy
por: Saigusa, Natsuki, et al.
Publicado: (2022)